NASDAQ:MNTA - Momenta Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $13.68 +1.12 (+8.92 %) (As of 02/18/2019 04:00 PM ET)Previous Close$12.56Today's Range$12.58 - $13.7952-Week Range$9.55 - $32.20Volume790,895 shsAverage Volume574,697 shsMarket Capitalization$1.35 billionP/E Ratio-11.40Dividend YieldN/ABeta2.04 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates. The company's novel therapeutics programs include M254, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy; M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; and M230, a recombinant trivalent human IgG1 Fc multimer to block tissue damage mediated by immune complexes. It has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts. Receive MNTA News and Ratings via Email Sign-up to receive the latest news and ratings for MNTA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:MNTA Previous Symbol CUSIP60877T10 Webwww.momentapharma.com Phone617-491-9700Debt Debt-to-Equity RatioN/A Current Ratio5.40 Quick Ratio5.40Price-To-Earnings Trailing P/E Ratio-11.40 Forward P/E Ratio-5.01 P/E GrowthN/A Sales & Book Value Annual Sales$138.88 million Price / Sales9.70 Cash FlowN/A Price / Cash FlowN/A Book Value$4.90 per share Price / Book2.79Profitability EPS (Most Recent Fiscal Year)($1.20) Net Income$-88,090,000.00 Net Margins-158.21% Return on Equity-44.72% Return on Assets-34.10%Miscellaneous Employees279 Outstanding Shares98,470,000Market Cap$1.35 billion OptionableOptionable Momenta Pharmaceuticals (NASDAQ:MNTA) Frequently Asked Questions What is Momenta Pharmaceuticals' stock symbol? Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA." How were Momenta Pharmaceuticals' earnings last quarter? Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) announced its quarterly earnings results on Thursday, August, 9th. The biotechnology company reported ($0.91) EPS for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.50. The biotechnology company earned $13 million during the quarter, compared to the consensus estimate of $15.83 million. Momenta Pharmaceuticals had a negative net margin of 158.21% and a negative return on equity of 44.72%. The firm's revenue was down 44.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.50) earnings per share. View Momenta Pharmaceuticals' Earnings History. When is Momenta Pharmaceuticals' next earnings date? Momenta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, February 22nd 2019. View Earnings Estimates for Momenta Pharmaceuticals. How can I listen to Momenta Pharmaceuticals' earnings call? Momenta Pharmaceuticals will be holding an earnings conference call on Friday, February 22nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8772249084. What price target have analysts set for MNTA? 4 brokerages have issued 1 year target prices for Momenta Pharmaceuticals' shares. Their forecasts range from $16.00 to $39.00. On average, they anticipate Momenta Pharmaceuticals' stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 119.3% from the stock's current price. View Analyst Price Targets for Momenta Pharmaceuticals. What is the consensus analysts' recommendation for Momenta Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Momenta Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Momenta Pharmaceuticals. What are Wall Street analysts saying about Momenta Pharmaceuticals stock? Here are some recent quotes from research analysts about Momenta Pharmaceuticals stock: 1. Stifel Nicolaus analysts commented, "During our recent meeting with management, MNTA highlighted additional data from its Phase 1 studies for M281, its anti-FcRn candidate, (see page 3) which indicates its 30 mg/kg did not lower albumin outside the normal range. We believe this is important as some investors remain skeptical around M281’s safety profile after MNTA’s R&D day which indicated M281 not only lowered IgG but also was modestly lowering albumin. In our recent deep dive on M281’s safety controversies, we believed its potency would allow MNTA a good deal of flexibility to find a regimen offering low/no albumin lowering while maintaining a high level of IgG reduction." (1/8/2019) 2. According to Zacks Investment Research, "The completion of the strategic review has narrowed Momenta's focus on its biosimilar portfolio. Momenta will now advance only two late-stage biosimilar assets, M923, its wholly-owned proposed biosimilar to Humira and M710, its proposed biosimilar to Eylea. Momenta will also restructure its executive team and reduce its workforce by approximately 50%. The cost savings from the restructuring plan should enable the company to develop novel drug candidates for the treatment of rare, immune-mediated diseases. While the FDA approval of Glatopa 40 mg should relieve Momenta, competition has limited market share gains for the company as Mylan has already won the FDA’s approval for the same. Shares of the company have underperformed the industry in the past twelve months." (1/7/2019) Has Momenta Pharmaceuticals been receiving favorable news coverage? News headlines about MNTA stock have been trending positive on Monday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Momenta Pharmaceuticals earned a daily sentiment score of 2.3 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the near term. Who are some of Momenta Pharmaceuticals' key competitors? Some companies that are related to Momenta Pharmaceuticals include argenx (ARGX), Ablynx (ABLYF), Allogene Therapeutics (ALLO), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Spark Therapeutics (ONCE), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Aerie Pharmaceuticals (AERI), Atara Biotherapeutics (ATRA), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Alector (ALEC) and Orchard Therapeutics (ORTX). Who are Momenta Pharmaceuticals' key executives? Momenta Pharmaceuticals' management team includes the folowing people: Mr. Craig A. Wheeler, Pres, CEO & Exec. Director (Age 59)Dr. Ganesh Venkataraman Kaundinya, Co-Founder & Consultant (Age 52)Dr. Santiago Arroyo, Chief Medical Officer & Sr. VP of Devel.Mr. Bruce A. Leicher, Consultant (Age 63)Mr. Scott M. Storer, Consultant Who are Momenta Pharmaceuticals' major shareholders? Momenta Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.99%), Perceptive Advisors LLC (2.87%), D. E. Shaw & Co. Inc. (2.64%), RA Capital Management LLC (2.60%), Dimensional Fund Advisors LP (1.14%) and Geode Capital Management LLC (1.08%). Company insiders that own Momenta Pharmaceuticals stock include Anthony M Manning, Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, Jo Ann Beltramello, Michelle Robertson, Santiago Arroyo, Scott M Storer and Young Kwon. View Institutional Ownership Trends for Momenta Pharmaceuticals. Which institutional investors are selling Momenta Pharmaceuticals stock? MNTA stock was sold by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P., New York State Common Retirement Fund, Bank of America Corp DE, KBC Group NV, PNC Financial Services Group Inc., Bank of Montreal Can, MetLife Investment Advisors LLC and Millennium Management LLC. Company insiders that have sold Momenta Pharmaceuticals company stock in the last year include Anthony M Manning, Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, Jo Ann Beltramello, Michelle Robertson, Santiago Arroyo and Young Kwon. View Insider Buying and Selling for Momenta Pharmaceuticals. Which institutional investors are buying Momenta Pharmaceuticals stock? MNTA stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, BlackRock Inc., RA Capital Management LLC, Westfield Capital Management Co. LP, D. E. Shaw & Co. Inc., Oregon Public Employees Retirement Fund, Monashee Investment Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for Momenta Pharmaceuticals. How do I buy shares of Momenta Pharmaceuticals? Shares of MNTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Momenta Pharmaceuticals' stock price today? One share of MNTA stock can currently be purchased for approximately $13.68. How big of a company is Momenta Pharmaceuticals? Momenta Pharmaceuticals has a market capitalization of $1.35 billion and generates $138.88 million in revenue each year. The biotechnology company earns $-88,090,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Momenta Pharmaceuticals employs 279 workers across the globe. What is Momenta Pharmaceuticals' official website? The official website for Momenta Pharmaceuticals is http://www.momentapharma.com. How can I contact Momenta Pharmaceuticals? Momenta Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-491-9700 or via email at [email protected] MarketBeat Community Rating for Momenta Pharmaceuticals (NASDAQ MNTA)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 463 (Vote Outperform)Underperform Votes: 468 (Vote Underperform)Total Votes: 931MarketBeat's community ratings are surveys of what our community members think about Momenta Pharmaceuticals and other stocks. Vote "Outperform" if you believe MNTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNTA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/18/2019 by MarketBeat.com StaffFeatured Article: What is the LIBOR?